The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation
Open accessAbstract
Background and objectives: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal duration of eculizumab treatment in atypical hemolytic uremic syndrome remains debated. We report on the French atypical hemolytic uremic syndrome working group’s first 2-year experience with eculizumab discontinuation in patients with atypical hemolytic uremic syndrome. Design, setting, participants & measurements: Using the French atypical hemolytic uremic syndrome registry database, we retrospectively identified all dialysis–free patients with atypical hemolytic uremic syndrome who discontinued eculizumab between 2010 and 2014 and reviewed their relevant clinical and biologic data. The decision to discontinue eculizumab was made by the clinician in charge of the patient. All patients were closely monitored by regular urine dipsticks and blood tests. Eculizumab was rapidly (24–48 hours) restarted in case of relapse. Results: Among 108 patients treated with eculizumab, 38 patients (nine children and 29 adults) discontinued eculizumab (median treatment duration of 17.5 months). Twenty-one patients (55%) carried novel or rare complement genes variants. Renal recovery under eculizumab was equally good in patients with and those without complement gene variants detected. After a median follow-up of 22 months, 12 patients (31%) experienced atypical hemolytic uremic syndrome relapse. Eight of 11 patients (72%) with complement factor H variants, four of eight patients (50%) with membrane cofactor protein variants, and zero of 16 patients with no rare variant detected relapsed. In relapsing patients, early reintroduction (≤48 hours) of eculizumab led to rapid (<7 days) hematologic remission and a return of serum creatinine to baseline level in a median time of 26 days. At last follow-up, renal function remained unchanged in nonrelapsing and relapsing patients compared with baseline values before eculizumab discontinuation. Conclusions: Pathogenic variants in complement genes were associated with higher risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Prospective studies are needed to identify biomarkers predictive of relapse and determine the best strategy of retreatment in relapsing patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Cited by
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Thrombotic Microangiopathy and the Kidney
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00620117 · Cited by 373
Jokiranta, T. S. (2017) · Blood · doi:10.1182/blood-2016-11-709865 · Cited by 280
Diseases of complement dysregulation-an overview
Wong, E. K. S., & Kavanagh, D. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0663-8 · Cited by 115
Gavriilaki, E., Anagnostopoulos, A., & Mastellos, D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00337 · Cited by 106
Metadata
- Authors
- Fakhouri, F., Fila, M., Provôt, F., Delmas, Y., Barbet, C., Châtelet, V., Rafat, C., Cailliez, M., Hogan, J., Servais, A., Karras, A., Makdassi, R., Louillet, F., Coindre, J.-P., Rondeau, E., Loirat, C., & Frémeaux-Bacchi, V.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-10-31
- Volume
- 12
- Issue
- 1
- Pages
- 50-59
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2540481111
- Cited by
- 194
- References
- 1
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. https://app.cochat.ai/papers/10.2215/cjn.06440616
- The paper
- Fakhouri, F., Fila, M., Provôt, F., Delmas, Y., Barbet, C., Châtelet, V., Rafat, C., Cailliez, M., Hogan, J., Servais, A., Karras, A., Makdassi, R., Louillet, F., Coindre, J.-P., Rondeau, E., Loirat, C., & Frémeaux-Bacchi, V. (2017). Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.06440616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.